 Clovis Oncology has had a rough 2021, with Rubraca sales continuing to disappoint. The companys Q3 sales revealed a slight increase quarter-over-quarter and a slight decrease year-over-year. The company points to COVID-19 headwinds and a decrease in the number of new ovarian cancer diagnoses. I am leaning more towards the lackluster demand for PARP inhibitors. 